{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:54:54Z","timestamp":1788454494733,"version":"build-2803163510"},"reference-count":45,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T00:00:00Z","timestamp":1648339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hemophilia A is characterized by unpredictable spontaneous bleeds and chronic comorbidities. However, limited data exists at the national level into detailed management patterns related to patient clinical characteristics, representative real\u2010world dosing and treatment frequency, and costs. To assess and characterize the US severe hemophilia A (SHA) population, including subgroups of patients, in terms of clinical and demographic characteristics, healthcare resource utilization received at hemophilia treatment centers (HTCs), and projected annual costs of treatment utilizing data from the ATHNdataset of the American Thrombosis and Hemostasis Network (ATHN). Adult male people with SHA (PwSHA) (FVIII\u00a0&lt;\u00a01%) were identified in the ATHNdataset between January 2013 and September 2019. This retrospective cohort study described patients\u2019 demographic and clinical characteristics, clinical history, as well as the HTC\u2010related health resource utilization (HRU), treatment utilization, and projected annual treatment costs of US PwSHA received over the most recent year. Results are reported for the overall population and for three mutually exclusive subpopulations of patients: PwSHA with a history of and\/or current inhibitors, PwSHA without a history of inhibitors but with (or a history of) one or more transfusion\u2010transmitted infections (hepatitis B virus [HBV], hepatitis C virus [HCV], or human immunodeficiency virus [HIV]), and PwSHA without a history of inhibitors or of transfusion\u2010transmitted infections (HBV, HCV, or HIV). Of the overall PwSHA cohort (<jats:italic>N<\/jats:italic>\u00a0=\u00a03677), there was a high prevalence of HCV (24.1%) and HIV (13.7%), while the prevalence of HBV (4.9%) was lower. Note that 20.5% of PwSHA overall currently or ever had FVIII inhibitors. On average, PwSHA had 2.8 total HTC visits per year, including 0.9 comprehensive care visits, 1.1 telephone contact visits, 0.5 office visits, and 0.1 surgeries or other procedures. However, 23.3% of PwSHA were not seen at an HTC, and 33.8% of PwSHA did not have a comprehensive care visit during their most recent year of data. HTC\u2010related HRU was similar between the overall cohort and across the patient subpopulations, although PwSHA and inhibitors had more frequent HTC visits (a mean of 3.6 visits annually vs. 2.5\u20132.8 in the other groups). Using reported treatment frequency and dosing, estimated mean annual hemophilia treatment costs varied by treatment and across the three subpopulations: extended half\u2010life factor product ($893,609\u2013934,301 by subpopulation), standard half\u2010life factor product ($798,700\u2013930,812), plasma\u2010derived factor product ($613,220\u2013801,061), and non\u2010factor product treatment ($765,289\u2014833,240). This study summarized recent sociodemographic and clinical characteristics, HTC\u2010related HRU, and HA treatments and projected costs among adult PwSHA, including among key subpopulations of PwSHA. PwSHA experience substantial clinical and resource burden on a chronic basis, despite the care coordination efforts of ATHN\u2010affiliated HTCs. These findings motivate further exploration of the drivers of resource utilization, observed differences across subpopulations and other disparities, and ongoing monitoring of clinical and treatment burden in the face of an evolving care landscape.<\/jats:p>","DOI":"10.1002\/jha2.412","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T02:23:51Z","timestamp":1648434231000},"page":"341-352","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Resource utilization and treatment costs of patients with severe hemophilia A: Real\u2010world data from the ATHNdataset"],"prefix":"10.1002","volume":"3","author":[{"given":"Michael","family":"Recht","sequence":"first","affiliation":[{"name":"American Thrombosis and Hemostasis Network (ATHN)  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunla","family":"He","sequence":"additional","affiliation":[{"name":"American Thrombosis and Hemostasis Network (ATHN)  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Er.","family":"Chen","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical, Inc. (BioMarin)  Novato CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunlei","family":"Cheng","sequence":"additional","affiliation":[{"name":"American Thrombosis and Hemostasis Network (ATHN)  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Solari","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical, Inc. (BioMarin)  Novato CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0219-9941","authenticated-orcid":false,"given":"David","family":"Hinds","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical, Inc. (BioMarin)  Novato CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,27]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"National Hemophilia Association.Hemophilia A.2020[cited 2021 Jan 7]. Available from:https:\/\/www.hemophilia.org\/bleeding\u2010disorders\u2010a\u2010z\/types\/hemophilia\u2010a"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118398258"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13998"},{"key":"e_1_2_9_6_1","unstructured":"Centers for Disease Control and Prevention.Data and statistics on hemophilia.2020[cited 2021 Jan 7]. Available from:https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/data.html"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/M19-1208"},{"key":"e_1_2_9_8_1","unstructured":"National Center on Birth Defects and Developmental Disabilities Centers for Disease Control and Prevention. CDC community counts: table 2. HTC population profile patient characteristics factor VIII and factor IX data reported from 1\/1\/2012 through 9\/29\/2021[cited 2021 Dec 20]https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/communitycounts\/data\u2010reports\/2021\u201009\/table\u20102\u2010factor.html"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615621"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10191"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14844"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1994.tb00815.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23957"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0000000000000175"},{"issue":"5","key":"e_1_2_9_16_1","first-page":"s126","article-title":"Economic costs of hemophilia and the impact of prophylactic treatment on patient management","volume":"22","author":"Chen SL","year":"2016","journal-title":"Am J Manag Care"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13758"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1016228"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13220"},{"key":"e_1_2_9_20_1","volume-title":"Healthcare resource use and costs associated with arthropathy in hemophilia A","author":"Patel A","year":"2018"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.3.316"},{"key":"e_1_2_9_22_1","unstructured":"CosgroveJ.Medicare: high\u2010expenditure part B drugs.2012. [cited 2020 Jan 19]. Available from:www.gao.gov\/assets\/650\/649459.pdf"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2581.2581"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2015.1002465"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25844"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20199"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006315"},{"key":"e_1_2_9_30_1","unstructured":"American Thrombosis and Hemostatis Network.Advancing research with better data through the ATHNdataset.2021[cited 2021 Jan 8]. Available from:https:\/\/athn.org\/what\u2010we\u2010do\/national\u2010projects\/athndataset.html"},{"key":"e_1_2_9_31_1","unstructured":"IBM Micromedex.Redbook.2020[cited 2021 Jan 19]. Available from:https:\/\/www.ibm.com\/products\/micromedex\u2010red\u2010book"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S325031"},{"key":"e_1_2_9_33_1","unstructured":"Centers for Disease Control and Prevention.Community counts registry report \u2013 males with hemophilia 2014\u20102017.2020.[cited 2021 April 30]. Available from:https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/communitycounts\/registry\u2010report\u2010males\/index.html"},{"key":"e_1_2_9_34_1","unstructured":"Centers for Disease Control and Prevention.HTC population profile.2020.[cited 2021 April 30]. Available from:https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/communitycounts\/data\u2010reports\/2020\u20109\/index.html"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100618"},{"key":"e_1_2_9_36_1","unstructured":"Hemophilia Federation of America.Blood safety.2020[cited Jan 19]. Available from:https:\/\/www.hemophiliafed.org\/our\u2010role\u2010and\u2010programs\/assisting\u2010and\u2010advocating\/policy\u2010priorities\/blood\u2010safety\/"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-675140"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15745"},{"issue":"3","key":"e_1_2_9_39_1","first-page":"361","article-title":"The management of hemophilia in elderly patients","volume":"2","author":"Franchini M","year":"2007","journal-title":"Clin Interv Aging"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.191"},{"issue":"1","key":"e_1_2_9_41_1","article-title":"Tailoring educational and behavioral interventions to level of health literacy: a systematic review","volume":"2","author":"Schapira MM","year":"2017","journal-title":"MDM Policy Pract"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13364"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14156"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.52"},{"key":"e_1_2_9_45_1","unstructured":"ICER.Hemophilia A.2020. Available from:https:\/\/icer\u2010review.org\/topic\/hemophilia\u2010a\/. Accessed 2 July 2022."},{"key":"e_1_2_9_46_1","unstructured":"Centers for Disease Control and Prevention.Inhibitors and hemophilia.2020[cited 2021 Jan 20]. Available from:https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/inhibitors.html"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.412","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T10:52:44Z","timestamp":1692874364000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,27]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/jha2.412"],"URL":"https:\/\/doi.org\/10.1002\/jha2.412","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,27]]},"assertion":[{"value":"2021-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}